OBJECTIVE: To study the efficacy and safety of Naoxintong capsule treatment of stroke recovery with Qi-deficiency and blood-stasis syndrome (cerebral infarction), and to compared the non-inferiority analysis with the positive drug Tongxinluo capsule. METHOD: Taking Tongxinluo capsules as control, randomized, double-blind, controlled, multi-center clinical experiments were studied. The evaluating indexes included the decrease of integral value of stroke patients, changes in traditional Chinese medicine, the improvement of the patient viability status (disability level), Chinese stroke scale (CSS), activities of daily living (DAL) scale and barthel index (BI ) points. RESULT: The total effect of the two groups, Chinese and other symptoms, showed no significant statistical significance. CONCLUSION:Naoxintong capsule stroke recovery, with Qi-deficiency and blood-stasis syndrome (cerebral infarction) has a therapeutic effect, and more secure.
RCT Entities:
OBJECTIVE: To study the efficacy and safety of Naoxintong capsule treatment of stroke recovery with Qi-deficiency and blood-stasis syndrome (cerebral infarction), and to compared the non-inferiority analysis with the positive drug Tongxinluo capsule. METHOD: Taking Tongxinluo capsules as control, randomized, double-blind, controlled, multi-center clinical experiments were studied. The evaluating indexes included the decrease of integral value of strokepatients, changes in traditional Chinese medicine, the improvement of the patient viability status (disability level), Chinese stroke scale (CSS), activities of daily living (DAL) scale and barthel index (BI ) points. RESULT: The total effect of the two groups, Chinese and other symptoms, showed no significant statistical significance. CONCLUSION: Naoxintong capsule stroke recovery, with Qi-deficiency and blood-stasis syndrome (cerebral infarction) has a therapeutic effect, and more secure.
Authors: Shuping Yuan; Jianhua Jin; Lu Chen; Yongzhong Hou; Hong Wang Journal: Evid Based Complement Alternat Med Date: 2017-02-15 Impact factor: 2.629
Authors: Yan Ma; Pei Zhao; Jinqiang Zhu; Chen Yan; Lin Li; Han Zhang; Meng Zhang; Xiumei Gao; Xiang Fan Journal: Evid Based Complement Alternat Med Date: 2016-02-02 Impact factor: 2.629
Authors: Bin Yu; Yao Yao; Xiaofeng Zhang; Ming Ruan; Zhennian Zhang; Li Xu; Tao Liang; Jinfu Lu Journal: Front Pharmacol Date: 2021-06-16 Impact factor: 5.810